Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP Followed by Alemtuzumab Consolidation in Refractory/Relapsed CLL
NCT00504491Phase 2Withdrawn
- Sponsor
- CABYC
- Start
- Jul 2007
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by CABYC. Planned start Jul 2007; status: withdrawn.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00504491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504491.